<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02616393</url>
  </required_header>
  <id_info>
    <org_study_id>KD019-206</org_study_id>
    <nct_id>NCT02616393</nct_id>
  </id_info>
  <brief_title>Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases</brief_title>
  <official_title>A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kadmon Corporation, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kadmon Corporation, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess the activity of tesevatinib in subjects with NSCLC and activating EGFR&#xD;
      mutations who have disease progression with Brain Metastases (BM) or Leptomeningeal&#xD;
      Metastases (LM) or who heave either BM or LM at initial presentation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">January 17, 2019</completion_date>
  <primary_completion_date type="Actual">January 17, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Activity of tesevatinib against BM using RECIST 1.1</measure>
    <time_frame>12 months</time_frame>
    <description>The primary objective is to evaluate the clinical activity of tesevatinib in subjects with non-small cell lung cancer (NSCLC), activating EGFR mutations, and BM as measured by RECIST 1.1 evaluated changes in BM size (Cohort A)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Activity of tesevatinib against LM using Symptom Resolution</measure>
    <time_frame>12 months</time_frame>
    <description>The primary objective is to evaluate the clinical activity of tesevatinib in subjects with NSCLC, activating EGFR mutations and/or LM as measured by improvement in CTCAE v4.03 symptoms and signs (Cohort B)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Activity of tesevatinib against BM at initial presentation using RECIST 1.1</measure>
    <time_frame>12 months</time_frame>
    <description>The primary objective is to evaluate the clinical activity of tesevatinib in subjects with non-small cell lung cancer (NSCLC), activating EGFR mutations, and BM at initial presentation as measured by RECIST 1.1 evaluated changes in BM size (Cohort C)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life in Subjects Receiving tesevatinib for BM</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate changes in Quality of Life (QOL) in subjects receiving tesevatinib for BM using the EORTC QLQ-C30 and EORTC QLQ-BN20 Questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life in Subjects Receiving tesevatinib for LM</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate changes in QOL in subjects receiving tesevatinib for LM using the EORTC QLQ-C30 and EORTC QLQ-BN20 Questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life in Subjects Receiving tesevatinib for BM at initial presentation</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate changes in QOL in subjects receiving tesevatinib for BM at initial presentation using the EORTC QLQ-C30 and EORTC QLQ-BN20 Questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Progression-Free Survival in Cohort A</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the median progression-free survival (PFS) in Cohort A by assessing the median number of days from Cycle 1, Day 1 until disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of CNS Non-Progression in Cohort A</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the rate of CNS non-progression at 3 and 6 months Cohort A by assessing the percentage of subjects in Cohort A without CNS disease progression 3 and 6 months after Cycle 1, Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-CNS Time to Progression in Cohort A</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the rate of Non-CNS time to progression in Cohort A by assessing the median number of days in Cycle 1, Day 1 until non-CNS disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CNS TTP in Cohort A</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the rate of CNS TTPin Cohort A by assessing the median number of days in Cycle 1, Day 1 to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Progression-Free Survival in Cohort B</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the median progression-free survival (PFS) in Cohort B by assessing the median number of days from Cycle 1, Day 1 until disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of CNS Non-Progression in Cohort B</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the rate of CNS non-progression at 3 and 6 months Cohort B by assessing the percentage of subjects in Cohort A without CNS disease progression 3 and 6 months after Cycle 1, Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-CNS Time to Progression in Cohort B</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the rate of Non-CNS time to progression in Cohort B by assessing the median number of days in Cycle 1, Day 1 until non-CNS disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CNS TTP in Cohort B</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the rate of CNS TTP in Cohort B by assessing the median number of days in Cycle 1, Day 1 to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival in Cohort A</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the median overall survival (OS) in Cohort A by measuring the median number of days from Cycle 1, Day 1 until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival in Cohort B</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the median OS in Cohort B by measuring the median number of days from Cycle 1, Day 1 until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Activity of tesevatinib against LM using Standard Cytology</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate the activity of tesevatinib in subjects with NSCLC as measured by decreases in NSCLC cells in the CSF using standard cytology as assessed by the percent change in the number of NSCLC cells in the CSF for each patient in cohort B from screening to Cycle 1, Day 14, from Day 14 to Cycle 3, Day 1, and from screening to Cycle 3, Day 1 (Cohort B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Activity of tesevatinib against LM using Improvement in MRI Findings</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate the activity of tesevatinib in subjects with NSCLC as measured by changes in MRI findings consistent with leptomeningeal metastases (absent or present) for each patient in Cohort B from Cycle 1, Day 1 to Cycle 3, Day 1 and from Cycle 1, Day 1 to Cycle 5 Day 1 (Cohort B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Progression-Free Survival in Cohort C</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the median progression-free survival (PFS) in Cohort C by assessing the median number of days from Cycle 1, Day 1 until disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of CNS Non-Progression in Cohort C</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the rate of CNS non-progression at 3 and 6 months Cohort C by assessing the percentage of subjects in Cohort C without CNS disease progression 3 and 6 months after Cycle 1, Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-CNS Time to Progression in Cohort C</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the rate of Non-CNS time to progression in Cohort C by assessing the median number of days in Cycle 1, Day 1 until non-CNS disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CNS TTP in Cohort C</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the rate of CNS TTPin Cohort C by assessing the median number of days in Cycle 1, Day 1 to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival in Cohort C</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the median overall survival (OS) in Cohort C by measuring the median number of days from Cycle 1, Day 1 until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics in Cohort B: Concentration of tesevatinib in CSF versus plasma</measure>
    <time_frame>12 Months</time_frame>
    <description>To evaluate the concentration of tesevatinib in CSF versus plasma in Cohort B by obtaining PK analysis of plasma pre-dose on both Cycle 1 Day 14 and Cycle 3 Day 1, as well as obtaining PK samples of both plasma and CSF 4-8 hours after tesevatinib administration on Cycle 1 Day 14 and on Cycle 3 Day 1.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Leptomeningeal Metastases</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Cohort A - Brain Metastases</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tesevatinib will be orally administered with a dose of 300 mg once daily to subjects with NSCLC who have progressed with BM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B - Leptomeningeal Metastases</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tesevatinib will be orally administered with a dose of 300 mg once daily to subjects with NSCLC who have progressed with LM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C - Brain Metastases at initial presentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tesevatinib will be orally administered with a dose of 300 mg once daily to subjects with NSCLC with BM at initial presentation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tesevatinib</intervention_name>
    <arm_group_label>Cohort A - Brain Metastases</arm_group_label>
    <arm_group_label>Cohort B - Leptomeningeal Metastases</arm_group_label>
    <arm_group_label>Cohort C - Brain Metastases at initial presentation</arm_group_label>
    <other_name>KD019, XL647</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Cohort A&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  History of NSCLC with EGFR mutation or an EGFR activating mutation that has had a&#xD;
             clinical response to erlotinib, afatinib, or gefitinib in the patient being enrolled.&#xD;
&#xD;
          -  Occurrence or progression of BM while receiving first line therapy (either erlotinib,&#xD;
             afatinib, or gefitinib) for at least 14 days. Patients may have received osimertinib&#xD;
             (or other agents inhibiting the T790M EGFR mutation) as second line therapy. If BM&#xD;
             progression occurs after osimertinib, patient will be eligible.&#xD;
&#xD;
          -  At least one measurable BM by RECIST 1.1 criteria (≥ 10mm in longest diameter). Target&#xD;
             lesions must not have received stereotactic radiotherapy (SRS). If subject had prior&#xD;
             whole brain radiotherapy (WBRT), progression in any measurable BM lesion must have&#xD;
             occurred at least 3 months after the end of WBRT. Subjects with asymptomatic brain&#xD;
             metastases may be enrolled without prior radiation therapy to the brain. Subjects with&#xD;
             minimally symptomatic brain metastases may be enrolled without prior radiation therapy&#xD;
             to the brain if they do not require immediate surgical or radiation therapy in the&#xD;
             opinion of the treating investigator and in the opinion of a radiation therapy or&#xD;
             neurosurgical consultant&#xD;
&#xD;
          -  Subjects in Cohort A may have asymptomatic LM detected by MRI. (Subjects with symptoms&#xD;
             or signs attributed to LM will be enrolled in Cohort B whether or not they have brain&#xD;
             metastases)&#xD;
&#xD;
          -  No clinically significant progression outside of the CNS on most recent EGFR inhibitor&#xD;
             therapy&#xD;
&#xD;
          -  ECOG Score ≤2&#xD;
&#xD;
          -  No history of another malignancy in the 5 years prior to study entry, except treated&#xD;
             non-melanoma skin cancer or superficial bladder cancer or carcinoma-in-situ of the&#xD;
             cervix or Stage 1 or 2 cancers of other sites that have been treated surgically and&#xD;
             have not recurred&#xD;
&#xD;
          -  Adequate organ and bone marrow functions&#xD;
&#xD;
          -  Serum potassium and magnesium levels above the lower limit of normal&#xD;
&#xD;
          -  No coexisting medical problems of sufficient severity to limit compliance with the&#xD;
             study&#xD;
&#xD;
          -  Willing and able to sign written informed consent and be able to comply with the study&#xD;
             protocol for the duration of the study&#xD;
&#xD;
          -  Women of childbearing potential (i.e., menstruating women) must have a negative urine&#xD;
             pregnancy test (positive urine tests are to be confirmed by serum test)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  First day of dosing with tesevatinib is less than 2 weeks from the last treatment of&#xD;
             cytotoxic chemotherapy, biological therapy, or immunotherapy, and less than 6 weeks&#xD;
             for nitrosoureas and mitomycin C. Surgical procedures must have been performed at&#xD;
             least 2 weeks prior to the start of study treatment. Subjects must have recovered from&#xD;
             the reversible effects of prior lung cancer treatments, including surgery and&#xD;
             radiation therapy (excluding alopecia)&#xD;
&#xD;
          -  First day of dosing with tesevatinib is less than 4 weeks from the last radiotherapy&#xD;
             of the brain or spinal cord/cauda equina&#xD;
&#xD;
          -  First day of dosing with tesevatinib is less than 2 weeks from treatment with another&#xD;
             investigational agent&#xD;
&#xD;
          -  Treatment with erlotinib must be discontinued at least 3 days prior to first dose of&#xD;
             tesevatinib and treatment with afatinib or other tyrosine kinase inhibitor must be&#xD;
             discontinued at least 3 days prior to first dose of tesevatinib&#xD;
&#xD;
          -  Any concurrent therapy for BM other than the specified treatment in this study&#xD;
&#xD;
          -  Taking any medication known to moderately or severely inhibit the CYP3A4 isozyme or&#xD;
             any drugs that are CYP3A4 inducers (including anti-epileptic agents such as&#xD;
             phenytoin). A stable regimen (≥ 4 weeks) of antidepressants of the SSRI class is&#xD;
             allowed (common SSRIs include escitalopram oxalate, citalopram, fluvoxamine,&#xD;
             paroxetine, sertraline, and fluoxetine)&#xD;
&#xD;
          -  Taking any drugs associated with torsades de pointes or known to moderately or&#xD;
             severely prolong the QTc(F) interval&#xD;
&#xD;
          -  Has evidence of active heart disease such as myocardial infarction within the 3 months&#xD;
             prior to study entry; symptomatic coronary insufficiency congestive heart failure;&#xD;
             moderate or severe pulmonary dysfunction&#xD;
&#xD;
          -  History of torsades de pointes, ventricular tachycardia or fibrillation, pathologic&#xD;
             sinus bradycardia (&lt; 50 bpm), heart block (excluding first degree block, being PR&#xD;
             interval only), or congenital long QT syndrome. Subjects with a history of atrial&#xD;
             arrhythmias should be discussed with the medical monitor&#xD;
&#xD;
          -  Has an active infectious process&#xD;
&#xD;
          -  Female subject who is pregnant or lactating&#xD;
&#xD;
          -  Known contraindication to MRI, such as cardiac pacemaker, shrapnel, or ocular foreign&#xD;
             body&#xD;
&#xD;
          -  Has marked prolongation of QTc(F) interval at screening or baseline (QTc[F] interval &gt;&#xD;
             470 msec) using the Fridericia method of correction for heart rate&#xD;
&#xD;
          -  Gastrointestinal (GI) condition that interferes with drug absorption&#xD;
&#xD;
          -  Non-malignant neurological disease that would interfere with evaluation of symptoms or&#xD;
             signs of brain metastases&#xD;
&#xD;
        Cohort B&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  History of NSCLC with EGFR mutation (either exon 19 deletion or L858R mutation) or, if&#xD;
             previously treated, history of an activating EGFR mutation that has had a clinical&#xD;
             response to erlotinib, afatinib, or gefitinib in the patient being enrolled).&#xD;
&#xD;
          -  Presentation with LM at initial presentation with no prior systemic treatment, or&#xD;
             occurrence or progression of LM while receiving first line therapy (either erlotinib,&#xD;
             afatinib, or gefitinib) for at least 14 days. Patients may have received osimertinib&#xD;
             (or other agents inhibiting the T790M EGFR mutation) as second line therapy. If LM&#xD;
             progression occurs after osimertinib, patient will be eligible.&#xD;
&#xD;
          -  Presence of at least one CTCAE 4.03 symptom/sign of at least Grade 1 attributed by the&#xD;
             investigator to leptomeningeal metastases&#xD;
&#xD;
          -  Diagnosis of LM by:&#xD;
&#xD;
               1. Cytological evidence in CSF sample of LM due to NSCLC, and/or&#xD;
&#xD;
               2. Findings on gadolinium-enhanced MRI&#xD;
&#xD;
          -  No clinically significant progression outside of the CNS on most recent EGFR inhibitor&#xD;
             therapy&#xD;
&#xD;
          -  Concomitant brain metastases and brain metastases previously treated with radiation&#xD;
             therapy are allowed. (Subjects with symptoms or signs attributed to LM will be&#xD;
             enrolled in Cohort B whether or not they have brain metastases)&#xD;
&#xD;
          -  ECOG Score ≤2&#xD;
&#xD;
          -  No history of another malignancy in the 5 years prior to study entry, except treated&#xD;
             non-melanoma skin cancer or superficial bladder cancer or carcinoma-in-situ of the&#xD;
             cervix or Stage 1 or 2 cancers of other sites that have been treated surgically and&#xD;
             have not recurred.&#xD;
&#xD;
          -  Adequate organ and bone marrow functions&#xD;
&#xD;
          -  Serum potassium and magnesium levels above the lower limit of normal&#xD;
&#xD;
          -  No coexisting medical problems of sufficient severity to limit compliance with the&#xD;
             study&#xD;
&#xD;
          -  Willing and able to sign written informed consent and be able to comply with the study&#xD;
             protocol for the duration of the study&#xD;
&#xD;
          -  Women of childbearing potential (i.e., menstruating women) must have a negative urine&#xD;
             pregnancy test (positive urine tests are to be confirmed by serum test)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  First day of dosing with tesevatinib is less than 2 weeks from the last treatment of&#xD;
             cytotoxic chemotherapy, biological therapy, or immunotherapy, and less than 6 weeks&#xD;
             for nitrosoureas and mitomycin C. Surgical procedures must have been performed at&#xD;
             least 2 weeks prior to the start of study treatment. Subjects must have recovered from&#xD;
             the reversible effects of prior lung cancer treatments, including surgery and&#xD;
             radiation therapy (excluding alopecia)&#xD;
&#xD;
          -  First day of dosing with tesevatinib is less than 4 weeks from the last radiotherapy&#xD;
             of the brain or spinal cord/cauda equina&#xD;
&#xD;
          -  First day of dosing with tesevatinib is less than 2 weeks from treatment with another&#xD;
             investigational agent&#xD;
&#xD;
          -  Treatment with erlotinib must be discontinued at least 3 days prior to first dose of&#xD;
             tesevatinib and treatment with afatinib or other tyrosine kinase inhibitor must be&#xD;
             discontinued at least 3 days prior to first dose of tesevatinib&#xD;
&#xD;
          -  Any concurrent therapy for LM other than the specified treatment in this study&#xD;
&#xD;
          -  Taking any medication known to moderately or severely inhibit the CYP3A4 isozyme or&#xD;
             any drugs that are CYP3A4 inducers (including anti-epileptic agents such as&#xD;
             phenytoin). A stable regimen (≥ 4 weeks) of antidepressants of the SSRI class is&#xD;
             allowed (common SSRIs include escitalopram oxalate, citalopram, fluvoxamine,&#xD;
             paroxetine, sertraline, and fluoxetine)&#xD;
&#xD;
          -  Taking any drugs associated with torsades de pointes or known to moderately or&#xD;
             severely prolong the QTc(F) interval&#xD;
&#xD;
          -  Has evidence of active heart disease such as myocardial infarction within the 3 months&#xD;
             prior to study entry; symptomatic coronary insufficiency congestive heart failure;&#xD;
             moderate or severe pulmonary dysfunction&#xD;
&#xD;
          -  History of torsades de pointes, ventricular tachycardia or fibrillation, pathologic&#xD;
             sinus bradycardia (&lt; 50 bpm), heart block (excluding first degree block, being PR&#xD;
             interval only), or congenital long QT syndrome. Subjects with a history of atrial&#xD;
             arrhythmias should be discussed with the medical monitor&#xD;
&#xD;
          -  Has an active infectious process&#xD;
&#xD;
          -  Female subject who is pregnant or lactating&#xD;
&#xD;
          -  Known contraindication to MRI, such as cardiac pacemaker, shrapnel, or ocular foreign&#xD;
             body&#xD;
&#xD;
          -  Has marked prolongation of QTc(F) interval at screening or baseline (QTc[F] interval &gt;&#xD;
             470 msec) using the Fridericia method of correction for heart rate&#xD;
&#xD;
          -  Gastrointestinal (GI) condition that interferes with drug absorption&#xD;
&#xD;
          -  Non-malignant neurological disease that would interfere with evaluation of symptoms or&#xD;
             signs of leptomeningeal metastases&#xD;
&#xD;
          -  Contraindications to lumbar puncture:&#xD;
&#xD;
               1. INR &gt; 1.5&#xD;
&#xD;
               2. Platelets &lt; 50 × 109/L (Note that platelets are required to be ≥100× 109/L at&#xD;
                  screening)&#xD;
&#xD;
               3. Therapeutic anticoagulant treatment that can't be held for 24 hours. Low dose low&#xD;
                  molecular weight heparin given for deep vein thrombosis (DVT) prophylaxis is&#xD;
                  allowed.&#xD;
&#xD;
               4. CNS lesions considered to be at risk for cerebral herniation, myelocompression,&#xD;
                  or conus/cauda compression&#xD;
&#xD;
        Cohort C&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  NSCLC with EGFR activating mutation&#xD;
&#xD;
          -  No prior systemic treatment for NSCLC. Treatment with systemic steroids is not&#xD;
             considered systemic treatment for NSCLC&#xD;
&#xD;
          -  No prior radiation therapy to the CNS (brain or spinal cord)&#xD;
&#xD;
          -  At least one measurable BM by RECIST 1.1 criteria (≥ 10mm in longest diameter) in a&#xD;
             subject with asymptomatic or minimally symptomatic brain metastases who does not&#xD;
             require immediate surgical or radiation therapy in the opinion of the treating&#xD;
             investigator and in the opinion of a radiation therapy or neurosurgical consultant.&#xD;
&#xD;
          -  Subjects in Cohort C may have asymptomatic LM detected by MRI&#xD;
&#xD;
          -  ECOG Score ≤2&#xD;
&#xD;
          -  No history of another malignancy in the 5 years prior to study entry, except treated&#xD;
             non-melanoma skin cancer or superficial bladder cancer or carcinoma-in-situ of the&#xD;
             cervix or Stage 1 or 2 cancers of other sites that have been treated surgically and&#xD;
             have not recurred&#xD;
&#xD;
          -  Adequate organ and bone marrow functions&#xD;
&#xD;
          -  Serum potassium and magnesium levels above the LLN&#xD;
&#xD;
          -  No coexisting medical problems of sufficient severity to limit compliance with the&#xD;
             study.&#xD;
&#xD;
          -  Willing and able to sign written informed consent and be able to comply with the study&#xD;
             protocol for the duration of the study&#xD;
&#xD;
          -  Women of childbearing potential (i.e., menstruating women) must have a negative urine&#xD;
             pregnancy test (positive urine tests are to be confirmed by serum test)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Surgical procedures that were performed less than 2 weeks prior to the start of study&#xD;
             treatment&#xD;
&#xD;
          -  Any concurrent therapy for BM other than the specified treatment in this study&#xD;
&#xD;
          -  Taking any medication known to moderately or severely inhibit the CYP3A4 isozyme or&#xD;
             any drugs that are CYP3A4 inducers (including anti-epileptic agents such as&#xD;
             phenytoin). A stable regimen (≥ 4 weeks) of antidepressants of the SSRI class is&#xD;
             allowed (common SSRIs include escitalopram oxalate, citalopram, fluvoxamine,&#xD;
             paroxetine, sertraline, and fluoxetine)&#xD;
&#xD;
          -  Taking any drugs associated with torsades de pointes or known to moderately or&#xD;
             severely prolong the QTc(F) interval&#xD;
&#xD;
          -  Has evidence of active heart disease such as myocardial infarction within the 3 months&#xD;
             prior to study entry; symptomatic coronary insufficiency congestive heart failure;&#xD;
             moderate or severe pulmonary dysfunction&#xD;
&#xD;
          -  History of torsades de pointes, ventricular tachycardia or fibrillation, pathologic&#xD;
             sinus bradycardia (&lt; 50 bpm), heart block (excluding first degree block, being PR&#xD;
             interval only), or congenital long QT syndrome. Subjects with a history of atrial&#xD;
             arrhythmias should be discussed with the medical monitor&#xD;
&#xD;
          -  Has an active infectious process&#xD;
&#xD;
          -  Female subject who is pregnant or lactating&#xD;
&#xD;
          -  Known contraindication to MRI, such as cardiac pacemaker, shrapnel, or ocular foreign&#xD;
             body&#xD;
&#xD;
          -  Has marked prolongation of QTc(F) interval at screening or Cycle 1 Day 1 (QTc[F]&#xD;
             interval &gt; 470 msec) using the Fridericia method of correction for heart rate&#xD;
&#xD;
          -  GI condition that interferes with drug absorption&#xD;
&#xD;
          -  Non-malignant neurological disease that would interfere with evaluation of symptoms or&#xD;
             signs of brain metastases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beverly Hills Cancer Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC Norris Oncology/Hematology Newport Beach</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Wayne Cancer Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>November 20, 2015</study_first_submitted>
  <study_first_submitted_qc>November 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2015</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>XL647</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 28, 2021</submitted>
    <returned>June 21, 2021</returned>
    <submitted>July 16, 2021</submitted>
    <returned>August 9, 2021</returned>
    <submitted>August 20, 2021</submitted>
    <returned>September 16, 2021</returned>
    <submitted>September 22, 2021</submitted>
    <returned>October 19, 2021</returned>
    <submitted>October 25, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

